Feng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Feng Zhang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chang Shu
State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication Huanzhong Su
1 shared publication- Jia Tianshuang
Department of Ultrasound, The 2nd Affiliated Hospital of Harbin Medical University, NO. 246, Xuefu Road, Nangang District, Harbin, 150081, Heilongjiang, China
1 shared publication - Litao Sun
Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China
1 shared publication Longcheng Hong
1 shared publication- Lu Rui
Department of Ultrasound, The 1st Affiliated Hospital of Hainan Medical University, NO. 31, Longhua Road, Longhua District, Haikou, 570102, Hainan, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 6136-6151
Identification of the immune subtypes associated with the prognosis and immunotherapy of metastatic melanoma
Background: Melanoma is an aggressive malignant tumor, characterized by high mortality. A growing amount of research indicates that the tumor immune microenvironment is closely associated with the survival outcomes and immunotherapy benefit for patients with advanced tumors. However, the molecular mechanisms underlying the effect of the tumor immune microenvironment on metastatic melanoma have not been clarified in detail. Therefore, this study aimed to identify potential effective immune-related tumor biomarkers for the prognosis and treatment of metastatic melanoma. Methods: Consensus clustering analysis was performed to identify robust clusters of metastatic melanoma in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) based on the nCounter immune gene expression profiles (NanoString). We used Estimation of Stromal and Immune Cells in Malignant Tumor Tissues Using Expression Data (ESTIMATE) and Cell-type Identification by Estimating Relative Subsets of Known RNA Transcripts (CIBERSORT) to study the microenvironment of different subtypes. Additionally, we constructed a prognostic model via binomial logistic regression analysis, and used an anti-programmed cell death 1 (anti-PD-1) immunotherapy cohort to validate the subtypes. Results: Two immune-associated clusters were identified in metastatic melanoma, with the immune-high subtype demonstrating a better clinical outcome than the Immune-Low subtype. Compared with the Immune-Low subtype, the immune-high subtype exhibited a significantly higher immune and stromal score, along with greater proportions of naïve B cells, plasma cells, CD8 T cells, memory activated CD4 T cells, activated natural killer (NK) cells, and M1 macrophages. Meanwhile, the proportion of resting NK cells, M0 macrophages, M2 macrophages, resting mast cells, and eosinophils were greater in the Immune-Low subtype. Elevated expressions of human leukocyte antigen (HLA) genes, immune checkpoint molecules, and T-cell receptor repertoire diversity were also observed in the Immune-High subtype, while the frequency of copy number variants was higher in the Immune-Low subtype. Furthermore, we constructed a 36-gene prognostic model, and the Immune-High subtype exhibited more benefit to immunotherapy. Conclusions: Our immune-associated model may have clinical implications for the prognosis and treatment guidance in patients with metastatic melanoma.
- 1 October 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 6136-6151
Open AccessIdentification of the immune subtypes associated with the prognosis and immunotherapy of metastatic melanoma
Background: Melanoma is an aggressive malignant tumor, characterized by high mortality. A growing amount of research indicates that the tumor immune microenvironment is closely associated with the survival outcomes and immunotherapy benefit for patients with advanced tumors. However, the molecular mechanisms underlying the effect of the tumor immune microenvironment on metastatic melanoma have not been clarified in detail. Therefore, this study aimed to identify potential effective immune-related tumor biomarkers for the prognosis and treatment of metastatic melanoma. Methods: Consensus clustering analysis was performed to identify robust clusters of metastatic melanoma in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) based on the nCounter immune gene expression profiles (NanoString). We used Estimation of Stromal and Immune Cells in Malignant Tumor Tissues Using Expression Data (ESTIMATE) and Cell-type Identification by Estimating Relative Subsets of Known RNA Transcripts (CIBERSORT) to study the microenvironment of different subtypes. Additionally, we constructed a prognostic model via binomial logistic regression analysis, and used an anti-programmed cell death 1 (anti-PD-1) immunotherapy cohort to validate the subtypes. Results: Two immune-associated clusters were identified in metastatic melanoma, with the immune-high subtype demonstrating a better clinical outcome than the Immune-Low subtype. Compared with the Immune-Low subtype, the immune-high subtype exhibited a significantly higher immune and stromal score, along with greater proportions of naïve B cells, plasma cells, CD8 T cells, memory activated CD4 T cells, activated natural killer (NK) cells, and M1 macrophages. Meanwhile, the proportion of resting NK cells, M0 macrophages, M2 macrophages, resting mast cells, and eosinophils were greater in the Immune-Low subtype. Elevated expressions of human leukocyte antigen (HLA) genes, immune checkpoint molecules, and T-cell receptor repertoire diversity were also observed in the Immune-High subtype, while the frequency of copy number variants was higher in the Immune-Low subtype. Furthermore, we constructed a 36-gene prognostic model, and the Immune-High subtype exhibited more benefit to immunotherapy. Conclusions: Our immune-associated model may have clinical implications for the prognosis and treatment guidance in patients with metastatic melanoma.